These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36303404)

  • 1. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
    Kato ET; Morrow DA; Guo J; Berg DD; Blazing MA; Bohula EA; Bonaca MP; Cannon CP; de Lemos JA; Giugliano RP; Jarolim P; Kempf T; Kristin Newby L; O'Donoghue ML; Pfeffer MA; Rifai N; Wiviott SD; Wollert KC; Braunwald E; Sabatine MS
    Eur Heart J; 2023 Jan; 44(4):293-300. PubMed ID: 36303404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
    Hagström E; James SK; Bertilsson M; Becker RC; Himmelmann A; Husted S; Katus HA; Steg PG; Storey RF; Siegbahn A; Wallentin L;
    Eur Heart J; 2016 Apr; 37(16):1325-33. PubMed ID: 26417057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
    Hagström E; Held C; Stewart RA; Aylward PE; Budaj A; Cannon CP; Koenig W; Krug-Gourley S; Mohler ER; Steg PG; Tarka E; Östlund O; White HD; Siegbahn A; Wallentin L;
    Clin Chem; 2017 Jan; 63(1):325-333. PubMed ID: 27811204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
    Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
    JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS.
    Zelniker TA; Jarolim P; Silverman MG; Bohula EA; Park JG; Bonaca MP; Scirica BM; Morrow DA
    Clin Chem Lab Med; 2019 Jun; 57(7):1084-1092. PubMed ID: 30710475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
    Sinha B; Ghosal S
    Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
    Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
    Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDF-15 at admission predicts cardiovascular death, heart failure, and bleeding outcomes in patients with CAD.
    Wang J; Zhang T; Xu F; Gao W; Chen M; Zhu H; Xu J; Yin X; Pang J; Zhang S; Wei M; Chen J; Liu Y; Yu X; Chew DP; Chen Y
    ESC Heart Fail; 2023 Oct; 10(5):3123-3132. PubMed ID: 37620152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy.
    Damman P; Kempf T; Windhausen F; van Straalen JP; Guba-Quint A; Fischer J; Tijssen JG; Wollert KC; de Winter RJ; Hirsch A;
    Int J Cardiol; 2014 Mar; 172(2):356-63. PubMed ID: 24502880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study).
    Schopfer DW; Ku IA; Regan M; Whooley MA
    Am Heart J; 2014 Feb; 167(2):186-192.e1. PubMed ID: 24439979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study.
    Lyu L; Xv C; Xu J; Liu Z; He Y; Zhu W; Lin L; Yang Q; Wei Y; Wang J; Huang T; Hao B; Liu H
    J Thromb Thrombolysis; 2024 Jul; ():. PubMed ID: 39068629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes.
    Peiró ÓM; García-Osuna Á; Ordóñez-Llanos J; Cediel G; Bonet G; Rojas S; Quintern V; Bardají A
    Clin Biochem; 2019 Nov; 73():62-69. PubMed ID: 31369736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth differentiation factor 15 predicts cardiovascular events in stable coronary artery disease.
    Wang J; Han LN; Ai DS; Wang XY; Zhang WJ; Xu XR; Liu HB; Zhang J; Wang P; Li X; Chen ML
    J Geriatr Cardiol; 2023 Jul; 20(7):527-537. PubMed ID: 37576485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
    Small AM; Pournamdari A; Melloni GEM; Scirica BM; Bhatt DL; Raz I; Braunwald E; Giugliano RP; Sabatine MS; Peloso GM; Marston NA; Natarajan P
    JAMA Cardiol; 2024 Apr; 9(4):385-391. PubMed ID: 38353970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
    Bouabdallaoui N; Claggett B; Zile MR; McMurray JJV; O'Meara E; Packer M; Prescott MF; Swedberg K; Solomon SD; Rouleau JL;
    Eur J Heart Fail; 2018 Dec; 20(12):1701-1709. PubMed ID: 30204280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Metab; 2021 Sep; 47(5):101249. PubMed ID: 33744399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.
    Batra G; Lindbäck J; Becker RC; Harrington RA; Held C; James SK; Kempf T; Lopes RD; Mahaffey KW; Steg PG; Storey RF; Swahn E; Wollert KC; Siegbahn A; Wallentin L
    J Am Coll Cardiol; 2022 Nov; 80(18):1735-1747. PubMed ID: 36302586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.